Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project

Abstract

Background Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings. Objective The aim of this study was to explore the potential of a large Italian multi-database distributed network for use in the postmarketing surveillance of biological drugs, including biosimilars, in patients with IMID. Methods A retrospective cohort study was conducted using 13 Italian regional claims databases during 2010–2019. A tailor-made R-based tool developed for distributed analysis of claims data using a study-specific common data model was customized for this study. We measured the yearly prevalence of biological drug users and the frequency of switches between originator and biosimilars for infliximab, etanercept, and adalimumab separately and stratified them by calendar year and region. We then calculated the cumulative number of users and person-years (PYs) of exposure to individual biological drugs approved for IMIDs. For a number of safety outcomes (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] infection), we conducted a sample power calculation to estimate the PYs of exposure required to investigate their association with individual biological drugs approved for IMIDs, considering different strengths of association. Results From a total underlying population of almost 50 million inhabitants from 13 Italian regions, we identified 143,602 (0.3%) biological drug users, with a cumulative exposure of 507,745 PYs during the entire follow-up. The mean age ± standard deviation of biological drug users was 49.3 ± 16.3, with a female-to-male ratio of 1.2. The age-adjusted yearly prevalence of biological drug users increased threefold from 0.7 per 1000 in 2010 to 2.1 per 1000 in 2019. Overall, we identified 40,996 users of biosimilars of tumor necrosis factor (TNF)-α inhibitors (i.e., etanercept, adalimumab, and infliximab) in the years 2015–2019. Of these, 46% ( N = 18,845) switched at any time between originator and biosimilars or vice versa. To investigate a moderate association (incidence rate ratio 2) between biological drugs approved for IMIDs and safety events of interest, such as optic neuritis (lowest background incidence rate 10.4/100,000 PYs) or severe infection (highest background incidence rate 4312/100,000 PYs), a total of 43,311 PYs and 104 PYs of exposure to individual biological drugs, respectively, would be required. As such, using this network, of 15 individual biological drugs approved for IMIDs, the association with those adverse events could be investigated for four (27%) and 14 (93%), respectively. Conclusion The VALORE project multi-database network has access to data on more than 140,000 biological drug users (and > 0.5 million PYs) from 13 Italian regions during the ye...

Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study

“…In the end, regional pseudonymized datasets were provided to the National Institute of Health for centralized analysis, in compliance with EU General Data Protection Regulation. Over the last 2 years, TheShinISS framework has been employed in several large scale observational studies exploring the association between several exposures and COVID-19 onset/ prognosis as well as other drug and vaccine-related research topics and is currently maintained by a collaborative research network [19,[26][27][28]. The relational scheme of the study databases as well as TheShinISS flow diagram is described in S1 Fig.…”

An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project

“…In Italy, during the last couple of years, many research networks have been created to study pharmacoepidemiologic and pharmacovigilance issues in several clinical areas, such as the monitoring of medication use during pregnancy ( Belleudi et al, 2021 ), the post-marketing surveillance of biological drugs ( Trifirò et al, 2021 ), and the assessment of the association between drugs, vaccines, and COVID-19 ( Ferroni et al, 2020 ; Trifirò et al, 2020 ; Massari et al, 2021 ; Spila Alegiani et al, 2021 ).…”

“…The CNT, which was established by Law 91/99 as the national competent authority for organ donation and transplantation activities (Italian National Transplant Center, 2022), contributes to the project through specific know-how regarding solid transplant area and sharing national data on solid organ transplants, collected prospectively, and then makes data available through an ad hoc data flow. The CDER collaborates to the project by specific pharmacoepidemiologic expertise and providing an R-based open-source tool, "TheShinISS," which was developed for distributed data analysis (Massari et al, 2020;Trifirò et al, 2021).…”

A New Era of Pharmacovigilance: Future Challenges and Opportunities

“…The combination of several claims databases may provide the statistical power needed to investigate the association between clinically relevant safety outcomes and specific drug exposure. In this regard, the Italian VALORE project is a good example of how the creation of a distributed network of administrative databases can have a great potential for conducting post-marketing surveillance of biological drugs, including biosimilars, in Italian patients affected by immunemediated inflammatory diseases (Trifirò et al, 2021).…”